阿达木单抗联合甲氨蝶呤与阿达木单抗单药治疗银屑病:单盲随机对照试验第一年结果
一项单盲随机对照试验比较阿达木单抗联合甲氨蝶呤10 mg/周(ADL-MTX组,31例)与阿达木单抗单药(ADL组,30例)治疗慢性斑块状银屑病。治疗1年后,ADL-MTX组抗药抗体阳性患者更少(22.6% vs 60.0%,P<0.01);PASI 75应答、药物生存率及血清谷浓度在两组间差异无统计学意义。
要点
- ADL-MTX组抗药抗体阳性率22.6%,ADL组60.0%,差异有统计学意义(P<0.01)。
- 第49周PASI 75应答率ADL-MTX组58.1% vs ADL组36.7%,差异无统计学意义(P=0.13)。
- 1年药物生存率ADL-MTX组74.2% vs ADL组58.6%,差异无统计学意义(P=0.15)。
核心结论
- 阿达木单抗联合甲氨蝶呤治疗使抗药抗体阳性患者更少,PASI 75应答、药物生存率及血清谷浓度有优于阿达木单抗单药的趋势。
- 两组患者报告结局和不良事件相当,未发生严重不良事件。
研究设计与样本
- 单盲随机对照试验,纳入慢性斑块状银屑病患者,比较阿达木单抗联合甲氨蝶呤10 mg/周(ADL-MTX组,31例)与阿达木单抗单药(ADL组,30例)。
- 评估疗效、安全性、药代动力学和免疫原性,随访1年。
主要发现
- 1年药物生存率ADL-MTX组74.2% vs ADL组58.6%(P=0.15),差异无统计学意义。
- 第49周PASI 75应答率ADL-MTX组58.1% vs ADL组36.7%(P=0.13),差异无统计学意义。
- 血清谷浓度中位数(四分位距)ADL-MTX组6.8(5.5‒9.2)mg/l vs ADL组5.9(3.5‒8.8)mg/l(P=0.26),差异无统计学意义。
- 抗药抗体阳性患者ADL-MTX组22.6% vs ADL组60.0%(P<0.01),ADL-MTX组更少。
- 未发生严重不良事件,两组患者报告结局和不良事件相当。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adalimumab is normally prescribed with methotrexate (MTX) in rheumatoid arthritis given the enhanced treatment effect and reduced antidrug antibody formation compared with adalimumab monotherapy (ADL). In psoriasis, the long-term treatment effects and pharmacokinetic profile have not been investigated extensively. METHODS: We conducted a randomized controlled trial to assess the efficacy, safety, pharmacokinetics, and immunogenicity of adalimumab combined with MTX 10 mg per week (ADL-MTX group) compared with that of ADL (ADL group) in chronic plaque psoriasis. RESULTS: A total of 31 patients in the ADL-MTX group and 30 in the ADL group were analyzed. After 1 year, a (nonsignificant) better drug survival was found in the ADL-MTX group (74.2 vs. 58.6%, P = 0.15). The PASI 75 response in week 49 was 58.1 versus 36.7% (P = 0.13), and the median (interquartile range) serum-trough concentrations were 6.8 (5.5‒9.2) versus 5.9 (3.5‒8.8) mg/l (P = 0.26) in the ADL-MTX group and ADL group, respectively. Fewer patients showed antidrug antibodies in the ADL-MTX group (22.6 vs. 60.0%, P < 0.01). No serious adverse events occurred. CONCLUSION: Combination therapy of adalimumab and MTX results in fewer patients showing antidrug antibodies, with a trend toward a better PASI 75 response, drug survival, and higher serum-trough concentrations than ADL. Patient-reported outcomes and adverse events were comparable between the groups.
引用
- van der Kraaij G, Busard C, van den Reek J, et al. Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial. J Invest Dermatol. 2022. PMID: 35276223. doi:10.1016/j.jid.2022.01.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。